HK Innoen Vice President Geunseok Song Receives Science and Technology Medal at '2026 Technology Developers Day'

Led the Development of Korea's 30th Novel Drug, K-CAB
"Pharmaceutical Competitiveness Begins with Continuous R&D"

HK Innoen announced on the 8th that Vice President Geunseok Song received the highest level decoration, the Medal of Science and Technology, at the '2026 Technology Developers Day' ceremony held the previous day at the Fairmont Ambassador Seoul in Yeouido, Seoul.

'Technology Developers Day' is a national memorial day designated to recognize the achievements and dedication of technology developers who have contributed to strengthening the nation's technological competitiveness. This year's ceremony, hosted by the Ministry of Science and ICT, was organized to spotlight the main contributors who have led private sector research and development. Vice President Song was awarded the third-class Order of Science and Technology Merit, 'Ungbijang,' in recognition of his contributions to technological innovation in Korea and his leadership in new drug development over 33 years in the R&D field.

Geunseok Song, Vice President of HK Innoen, is receiving the Science and Technology Medal at the '2026 Technology Developer's Day' ceremony held on the 7th at the Fairmont Ambassador Seoul in Yeouido, Seoul. HK Innoen

He led the new drug research and development at HK Innoen, overseeing the development of K-CAB, the 30th domestically developed novel drug. K-CAB, a next-generation P-CAB class treatment for gastroesophageal reflux disease that compensates for the limitations of existing therapies, expanded treatment options for patients. K-CAB has been exported to 55 countries, proving its competitiveness in the global market, and is regarded as a representative R&D achievement that strengthened the foundation for technological self-reliance in Korea’s new drug development sector.

Vice President Song commented, "The competitiveness of the pharmaceutical and biotech industries begins with technological innovation through continued research and development. Based on HK Innoen’s unique R&D capabilities, including the development of innovative new drugs such as K-CAB, we will continue to introduce globally competitive new drugs and contribute to enhancing the stature of Korea’s pharmaceutical and biotech industries."

This content was produced with the assistance of AI translation services.